Vivid Dx develops a direct-from-blood infectious disease diagnostic platform that combines advanced sample preparation, Raman spectroscopy, proprietary spectral databases, and AI-powered signal interpretation to identify pathogens and support phenotypic antimicrobial susceptibility testing. The company has reported preclinical proof-of-concept across core components and claims roughly 99% pathogen identification accuracy and about 92% concordance for phenotypic AST versus gold-standard methods. Vivid Dx is preparing to test its platform with patient-derived clinical samples as a key step toward clinical validation. The company plans to use recently raised seed capital to advance clinical validation and move toward commercialization. Keith O'Neill was appointed CEO to lead the next phase of clinical and commercial development. Vivid Dx is backed by Oxford Science Enterprises, Cedars-Sinai, Jameel Investment Management Company, and additional strategic investors.

Total raised

$15M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2026